[{"id":"e829fb14-3e34-428f-ab59-c6d18b40607d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02922764","created_at":"2021-01-18T14:21:03.943Z","updated_at":"2024-07-02T16:35:29.345Z","phase":"Phase 1","brief_title":"A Study of RGX-104 in Patients With Advanced Lung \u0026 Endometrial Cancer","source_id_and_acronym":"NCT02922764","lead_sponsor":"Inspirna, Inc.","biomarkers":" EGFR • ALK • CTLA4 • APOE","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • ALK • CTLA4 • APOE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-11-14"}]